@article{66c6a2eb06744d82aa34a8ed02ab698c,
title = "Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy",
abstract = "OBJECTIVES: We investigated whether the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are major regulators of glucose tolerance through the stimulation of insulin secretion, contribute to impaired glucose tolerance (IGT) among HIV-infected patients on highly active antiretroviral therapy (HAART). METHODS: Eighteen HIV-infected male patients (six lipodystrophic and 12 nonlipodystrophic) with normal glucose tolerance (NGT) were compared with 10 HIV-infected male patients (eight lipodystrophic and two nonlipodystrophic) with IGT. Plasma concentrations of GLP-1 and GIP were determined frequently during a 3-h, 75-g glucose tolerance test. Insulin secretion rates (ISRs) were calculated by deconvolution of C-peptide concentrations. RESULTS: The incremental area under the curve (incrAUC) for GLP-1 was increased by 250% in IGT patients compared with NGT patients (1455+/-422 vs. 409+/-254 pmol/L/180 min, respectively; P<0.05), whereas the incrAUC for GIP did not differ between the study groups (7689+/-1097 vs. 8041+/-998 pmol/L/180 min, respectively; not significant). In pooled study groups, the GIP incrAUC correlated positively with the ISR incrAUC without adjustment (r=0.38, P<0.05) and following adjustment for glucose incrAUC (r=0.49, P<0.01). CONCLUSIONS: Our data suggest: (1) that glucose-intolerant, HIV-infected male patients may display enhanced GLP-1 responses to oral glucose compared with normal glucose-tolerant HIV-infected male patients, which may represent a compensatory mechanism rather than explain the IGT; (2) that the GIP response may be associated with ISR independently of plasma glucose in nondiabetic HIV-infected males on HAART.",
keywords = "Adult, Analysis of Variance, Antiretroviral Therapy, Highly Active, Antiviral Agents, Area Under Curve, Blood Glucose, Body Composition, C-Peptide, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose, Glucose Intolerance, Glucose Tolerance Test, HIV Infections, HIV-Associated Lipodystrophy Syndrome, Humans, Male, Peptide Fragments, Protein Precursors",
author = "O Andersen and Haugaard, {S B} and Holst, {J J} and Deacon, {C F} and J Iversen and Andersen, {U B} and Nielsen, {Jens Ole} and S Madsbad",
year = "2005",
doi = "10.1111/j.1468-1293.2005.00270.x",
language = "English",
volume = "6",
pages = "91--8",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "2",
}